Crispr Therapeutics AG vs Western Alliance Bancorporation — how do they compare? Crispr Therapeutics AG trades at $53.97 (market cap $5.23B), while Western Alliance Bancorporation trades at $81.46 (market cap $8.89B). The key difference: Western Alliance Bancorporation is the larger of the two by market cap, and Western Alliance Bancorporation pays a 2.06% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | WAL | |
|---|---|---|
Market Cap | $5.23B | $8.89B |
Sector | Health | Financials |
52-Week High | $76.78 | $96.08 |
52-Week Low | $44.34 | $66.70 |
Enterprise Value | $3.65B | — |
Dividend Yield | — | 2.06% |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →